HSIC Stock Might Rise Following the Acquisition of Acentus
With the latest acquisition of Acentus, Henry Schein’s homecare medical products platform will now have an annual revenue base of approximately $350 million. Accordingly, we expect market sentiment to ...
Henry Schein (HSIC) Gets a Hold from Evercore ISI
Evercore ISI analyst Elizabeth Anderson CFA maintained a Hold rating on Henry Schein (HSIC – Research Report) yesterday and set a price target ...
Calculating The Fair Value Of Henry Schein, Inc. (NASDAQ:HSIC)
The projected fair value for Henry Schein is US$67.04 based on 2 Stage Free Cash Flow to Equity With US$70.70 share price, Henry Schein appears to be trading close to its estimated fair value ...
Hosted on MSN11d
B of A Securities Upgrades Henry Schein (HSIC)
Fintel reports that on January 6, 2025, B of A Securities upgraded their outlook for Henry Schein (NasdaqGS:HSIC) from ...
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Henry Schein, Inc. (NASDAQ:HSIC) Given Average Rating of “Moderate Buy” by Brokerages
Shares of Henry Schein, Inc. (NASDAQ:HSIC – Get Free Report) have been assigned an average recommendation of “Moderate Buy” ...
Business Wire2d
Henry Schein Completes Acquisition of Acentus
The Acentus transaction follows Henry Schein’s acquisition of Prism Medical Products, LLC in 2021 and Shield Healthcare and ...
MassDevice2d
Henry Schein completes acquisition of CGM supplier Acentus
Tampa, Florida-based Acentus, a national medical supplier, specializes in the delivery of continuous glucose monitors (CGMs).
Nasdaq26d
B of A Securities Upgrades Henry Schein (HSIC)
Fintel reports that on January 6, 2025, B of A Securities upgraded their outlook for Henry Schein (NasdaqGS:HSIC) from Underperform to Buy. As of December 23, 2024, the average one-year price ...